244 related articles for article (PubMed ID: 18245648)
1. Childhood polycythemia vera and essential thrombocythemia: does their pathogenesis overlap with that of adult patients?
Teofili L; Foà R; Giona F; Larocca LM
Haematologica; 2008 Feb; 93(2):169-72. PubMed ID: 18245648
[No Abstract] [Full Text] [Related]
2. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
[TBL] [Abstract][Full Text] [Related]
3. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
4. PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia.
Passamonti F; Pietra D; Rumi E; Arcaini L; Della Porta MG; Malcovati L; Pascutto C; Lazzarino M; Cazzola M
Leukemia; 2005 May; 19(5):888-9. PubMed ID: 15744342
[No Abstract] [Full Text] [Related]
5. Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera.
Ganly P; Hanrahan V; Baker B; Romeril K
Am J Hematol; 2007 Jan; 82(1):80-2. PubMed ID: 16924638
[TBL] [Abstract][Full Text] [Related]
6. Current evaluation of the clinical, diagnostic, and therapeutic usefulness of prv-1 and c-mpl markers in polycythemia vera and essential thrombocythemia.
Pahl HL
Clin Adv Hematol Oncol; 2004 Apr; 2(4):202, 204. PubMed ID: 16163180
[No Abstract] [Full Text] [Related]
7. Difficulty distinguishing essential thrombocythaemia from polycythaemia vera in children with JAK2 V617F-positive myeloproliferative neoplasms.
Kucine N; Al-Kawaaz M; Hajje D; Bussel J; Orazi A
Br J Haematol; 2019 Apr; 185(1):136-139. PubMed ID: 29767848
[No Abstract] [Full Text] [Related]
8. Diagnostic approaches to polycythemia vera in 2004.
Pahl HL
Expert Rev Mol Diagn; 2004 Jul; 4(4):495-502. PubMed ID: 15225097
[TBL] [Abstract][Full Text] [Related]
9. Frequency and clinical features of the JAK2 V617F mutation in pediatric patients with sporadic essential thrombocythemia.
Nakatani T; Imamura T; Ishida H; Wakaizumi K; Yamamoto T; Otabe O; Ishigami T; Adachi S; Morimoto A
Pediatr Blood Cancer; 2008 Dec; 51(6):802-5. PubMed ID: 18802948
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of PRV-1 gene in polycythemia rubra vera and essential thrombocythemia.
Martini M; Teofili L; Larocca LM
Methods Mol Med; 2006; 125():265-73. PubMed ID: 16502591
[TBL] [Abstract][Full Text] [Related]
11. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
[TBL] [Abstract][Full Text] [Related]
12. Myeloproliferative neoplasms 2012: the John M. Bennett 80th birthday anniversary lecture.
Tefferi A
Leuk Res; 2012 Dec; 36(12):1481-9. PubMed ID: 22917768
[TBL] [Abstract][Full Text] [Related]
13. JAK2 V617F mutation and PRV-1 overexpression: relevance in the diagnosis of polycythaemia vera and essential thrombocythaemia.
Melis S; Vellinga S; Zachée P; Sierens AC; De Schouwer PJ
Acta Clin Belg; 2009; 64(5):429-33. PubMed ID: 19999391
[TBL] [Abstract][Full Text] [Related]
14. MPL W515L mutation in pediatric essential thrombocythemia.
Farruggia P; D'Angelo P; La Rosa M; Scibetta N; Santangelo G; Lo Bello A; Duner E; Randi ML; Putti MC; Santoro A
Pediatr Blood Cancer; 2013 Aug; 60(8):E52-4. PubMed ID: 23441089
[TBL] [Abstract][Full Text] [Related]
15. Essential thrombocythemia vs. early/prefibrotic myelofibrosis: why does it matter.
Barosi G
Best Pract Res Clin Haematol; 2014 Jun; 27(2):129-40. PubMed ID: 25189724
[TBL] [Abstract][Full Text] [Related]
16. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
Zhan H; Spivak JL
Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
[TBL] [Abstract][Full Text] [Related]
17. It is time to change thrombosis risk assessment for PV and ET?
Passamonti F; Caramazza D; Mora B; Casalone R; Maffioli M
Best Pract Res Clin Haematol; 2014 Jun; 27(2):121-7. PubMed ID: 25189723
[TBL] [Abstract][Full Text] [Related]
18. Masked polycythaemia vera is genetically intermediate between JAK2V617F mutated essential thrombocythaemia and overt polycythaemia vera.
Tiong IS; Casolari DA; Nguyen T; Van Velzen MJ; Ambler K; D'Andrea RJ; Ross DM
Blood Cancer J; 2016 Aug; 6(8):e459. PubMed ID: 27540717
[No Abstract] [Full Text] [Related]
19. The rate of transformation from JAK2-mutated ET to PV is influenced by an accurate WHO-defined clinico-morphological diagnosis.
Barbui T; Thiele J; Carobbio A; Vannucchi AM; Tefferi A
Leukemia; 2015 Apr; 29(4):992-3. PubMed ID: 25425199
[No Abstract] [Full Text] [Related]
20. PRV-1 mRNA expression discriminates two types of essential thrombocythemia.
Griesshammer M; Klippel S; Strunck E; Temerinac S; Mohr U; Heimpel H; Pahl HL
Ann Hematol; 2004 Jun; 83(6):364-70. PubMed ID: 15034760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
